Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0TVXVM
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
h3E1-MMAE ADC
|
|||||
| Synonyms |
h3E1-MMAE ADC
Click to Show/Hide
|
|||||
| Organization |
Kindai University; Pharma Foods International Co., Ltd.
|
|||||
| Drug Status |
Investigative
|
|||||
| Structure |
|
|||||
| Antibody Name |
h3E1
|
Antibody Info | ||||
| Antigen Name |
Cell adhesion molecule 1 (CADM1)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mc-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteine.
|
|||||
| Combination Type |
Vedotin
|
|||||
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 2.04 nM | Positive CADM1 expression (CADM1+++/++) | ||
| Method Description |
Killing of endometrial adenocarcinoma cells by h3E1-MMAE ADC. Endometrial adenocarcinoma cells were cultured in a 96-well plate at 30% confluence, and either hIgG-MMAE or h3E1-MMAE ADC was added at indicated concentrations. After 5 days, cell viability was calculated by WST-8 assays in triplicate. The mean is plotted in a line graph, with a thin vertical line indicating the standard deviation. a and b, P-value <.05 and .01, respectively, when compared with the value of h3E1-MMAE ADC at the identical concentration. IC50 (ug/ml and nM) is calculated.
Click to Show/Hide
|
||||
| In Vitro Model | Type II endometrial adenocarcinoma | HEC-50B cells | CVCL_2929 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 12.02 nM | Positive CADM1 expression (CADM1+++/++) | ||
| Method Description |
Killing of endometrial adenocarcinoma cells by h3E1-MMAE ADC. Endometrial adenocarcinoma cells were cultured in a 96-well plate at 30% confluence, and either hIgG-MMAE or h3E1-MMAE ADC was added at indicated concentrations. After 5 days, cell viability was calculated by WST-8 assays in triplicate. The mean is plotted in a line graph, with a thin vertical line indicating the standard deviation. a and b, P-value <.05 and .01, respectively, when compared with the value of h3E1-MMAE ADC at the identical concentration. IC50 (ug/ml and nM) is calculated.
Click to Show/Hide
|
||||
| In Vitro Model | Endometrial adenocarcinoma | HEC-1B cells | CVCL_0294 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 13.03 nM | Positive CADM1 expression (CADM1+++/++) | ||
| Method Description |
Killing of endometrial adenocarcinoma cells by h3E1-MMAE ADC. Endometrial adenocarcinoma cells were cultured in a 96-well plate at 30% confluence, and either hIgG-MMAE or h3E1-MMAE ADC was added at indicated concentrations. After 5 days, cell viability was calculated by WST-8 assays in triplicate. The mean is plotted in a line graph, with a thin vertical line indicating the standard deviation. a and b, P-value <.05 and .01, respectively, when compared with the value of h3E1-MMAE ADC at the identical concentration. IC50 (ug/ml and nM) is calculated.
Click to Show/Hide
|
||||
| In Vitro Model | Uveal melanoma | OCM-2 cells | CVCL_6936 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 24.32 nM | Positive CADM1 expression (CADM1+++/++) | ||
| Method Description |
Killing of endometrial adenocarcinoma cells by h3E1-MMAE ADC. Endometrial adenocarcinoma cells were cultured in a 96-well plate at 30% confluence, and either hIgG-MMAE or h3E1-MMAE ADC was added at indicated concentrations. After 5 days, cell viability was calculated by WST-8 assays in triplicate. The mean is plotted in a line graph, with a thin vertical line indicating the standard deviation. a and b, P-value <.05 and .01, respectively, when compared with the value of h3E1-MMAE ADC at the identical concentration. IC50 (ug/ml and nM) is calculated.
Click to Show/Hide
|
||||
| In Vitro Model | Endometrial adenocarcinoma | JHUM-3 cells | CVCL_4657 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | > 1000 nM | Negative CADM1 expression (CADM1 -) | ||
| Method Description |
Killing of endometrial adenocarcinoma cells by h3E1-MMAE ADC. Endometrial adenocarcinoma cells were cultured in a 96-well plate at 30% confluence, and either hIgG-MMAE or h3E1-MMAE ADC was added at indicated concentrations. After 5 days, cell viability was calculated by WST-8 assays in triplicate. The mean is plotted in a line graph, with a thin vertical line indicating the standard deviation. a and b, P-value <.05 and .01, respectively, when compared with the value of h3E1-MMAE ADC at the identical concentration. IC50 (ug/ml and nM) is calculated.
Click to Show/Hide
|
||||
| In Vitro Model | Endometrial adenocarcinoma | HHUA cells | CVCL_3866 | ||
References